New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures
Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing
QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts
Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion
VENLO, Netherlands & HILDEN, Germany, July 14, 2026--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe.
The new QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour. It complements the recently launched QIAstat-Dx BCID GPF Plus AMR Panel in Europe, extending QIAGEN's bloodstream infection testing coverage across gram-positive bacteria, gram-negative bacteria, fungi and key AMR markers. Together, the two panels detect 33 pathogen targets and 28 AMR markers, enabling rapid identification of the most clinically relevant bloodstream pathogens and resistance mechanisms to support earlier pathogen identification and clinical decision-making.
"Every hour matters when treating bloodstream infections, particularly when AMR is involved," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. "Together, our complementary BCID panels provide comprehensive molecular coverage of the pathogens and resistance mechanisms most relevant to bloodstream infections. By delivering results in about one hour, they help laboratories support faster treatment decisions, antimicrobial stewardship and effective infection control."
Gram-negative pathogens are among the leading causes of bloodstream infections and are frequently associated with AMR, one of the world's most significant public health threats. AMR occurs when bacteria develop mechanisms that render antibiotics ineffective, making infections more difficult to treat and increasing the risk of severe illness and death. In bloodstream infections, delays in identifying resistant pathogens can postpone appropriate therapy, while the growing burden of beta-lactam resistance driven by extended-spectrum beta-lactamase (ESBL) and carbapenemase-producing organisms underscores the need for rapid and accurate detection. With broad coverage of key beta-lactam resistance mechanisms, the QIAstat-Dx BCID GN Plus AMR Panel provides rapid, actionable molecular insights to support optimized treatment decisions and infection control.